Activity and survival benefit of second-line chemotherapy (2L-Ctx) in advanced pancreatic adenocarcinoma (APC): Pooled analysis of the literature.
MinYuen Teo
No relevant relationships to disclose
Raymond S. McDermott
No relevant relationships to disclose